Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 147 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Coronary Stent Occlusion Clear all
Completed Not applicable Interventional Results available

Abbott Next Generation Drug Eluting Stent 48mm Study

NCT04282148
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
ABT NG DES 48 EECSS
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
18
States / cities
Scottsdale, Arizona • La Jolla, California • Santa Monica, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Jul 22, 2026, 5:15 AM EDT
Recruiting Not applicable Interventional

MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions

NCT05908331
View directory record Official record
Conditions
In-Stent Restenosis, Cardiovascular Diseases, Coronary Artery Disease
Interventions
Sirolimus Drug Coated Balloon, Plan balloon Angioplasty (POBA)
Device
Lead sponsor
Concept Medical Inc.
Industry
Eligibility
18 Years to 110 Years
Enrollment
492 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
27
States / cities
Birmingham, Alabama • Gilbert, Arizona • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Jul 22, 2026, 5:15 AM EDT
Not listed No phase listed Observational

Impact of Coronary Artery Stenting on Quantitative Myocardial Blood Flow and Health Status

NCT04475094
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Rubidium-82, Seattle Angina Questionnaire-7, Rose Dyspnea Scale
Drug · Behavioral
Lead sponsor
Cardiovascular Imaging Technologies
Industry
Eligibility
18 Years to 90 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Jul 22, 2026, 5:15 AM EDT
Completed Not applicable Interventional Results available

An Evaluation of the Commercially Available Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System

NCT01638507
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Resolute Integrity Stent
Device
Lead sponsor
Medtronic Vascular
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Jul 22, 2026, 5:15 AM EDT
Completed Not applicable Interventional Results available

Wall Shear Stress and Neointimal Healing Following PCI in Angulated Coronary Vessels

NCT02098876
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Resolute Integrity Zotarolimus eluting stent, Xience Xpedition everolimus eluting stent, Optical Coherence Tomography (OCT), Intravascular Ultrasound (IVUS)
Device
Lead sponsor
Emory University
Other
Eligibility
30 Years to 80 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 8, 2022 · Synced Jul 22, 2026, 5:15 AM EDT
Completed No phase listed Observational

Drug Eluting Stent Registry of Thrombosis

NCT00812552
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
984 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
18
States / cities
Sacramento, California • Washington D.C., District of Columbia • Springfield, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Jul 22, 2026, 5:15 AM EDT
Completed Not applicable Interventional Results available

Rotational Atherectomy Combined With Cutting Balloon to Optimize Stent Expansion in Calcified Lesions

NCT04865588
View directory record Official record
Conditions
Coronary Artery Disease, Atherosclerosis
Interventions
rotational atherectomy, cutting balloon, plain old balloon
Procedure · Device
Lead sponsor
Samin Sharma, M.D., F.A.C.C., M.S.C.A.I.
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
New York, New York • Roslyn, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Jul 22, 2026, 5:15 AM EDT
Completed Not applicable Interventional Results available

Absorb IV Randomized Controlled Trial

NCT02173379
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
Interventions
Absorb BVS, XIENCE
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
98
States / cities
Birmingham, Alabama • Chandler, Arizona • Gilbert, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2023 · Synced Jul 22, 2026, 5:15 AM EDT
Completed Phase 4 Interventional Results available

PROMUS Element Plus US Post-Approval Study

NCT01589978
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PROMUS Element Plus Coronary Stent System, Aspirin, P2Y12 antagonist
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
Not listed
Enrollment
2,681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
52
States / cities
Huntsville, Alabama • Mobile, Alabama • Jonesboro, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Jul 22, 2026, 5:15 AM EDT
Completed Phase 4 Interventional Results available

EDUCATE: The MEDTRONIC Endeavor Drug Eluting Stenting: Understanding Care, Antiplatelet Agents and Thrombotic Events

NCT01069003
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Placebo Arm, Thienopyridine Therapy, Surveillance Arm
Drug · Device
Lead sponsor
Medtronic Vascular
Industry
Eligibility
19 Years and older
Enrollment
2,272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Anderson, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 19, 2016 · Synced Jul 22, 2026, 5:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Clearance Of Mucus In Stents (COMIS)

NCT01370278
View directory record Official record
Conditions
Lung Neoplasms, Respiratory Failure, Pneumonia, Acute Coronary Syndromes, Unstable Angina, Myocardial Infarction, Cardiac Arrhythmia, Thromboembolic Disease
Interventions
Normal Saline, Sodium Bicarbonate
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Jul 22, 2026, 5:15 AM EDT
Completed Phase 3 Interventional

Study of the 4.0mm Sirolimus-Eluting Stent in the Treatment of Patients With Coronary Artery Lesions

NCT00232752
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
4.0 CYPHER Sirolimus-Eluting Coronary Stent
Device
Lead sponsor
Cordis US Corp.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 1, 2009 · Synced Jul 22, 2026, 5:15 AM EDT
Completed No phase listed Observational Results available

XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study

NCT01249027
View directory record Official record
Conditions
Angioplasty, Chronic Coronary Occlusion, Stent Thrombosis, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
2,605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2019 · Synced Jul 22, 2026, 5:15 AM EDT
Completed Phase 3 Interventional

Direct Stenting of TAXUS Liberté™-SR Stent for the Treatment of Patients With de Novo Coronary Artery Lesions

NCT00371423
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
TAXUS Liberté™-SR
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
18
States / cities
Little Rock, Arkansas • Sacramento, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2012 · Synced Jul 22, 2026, 5:15 AM EDT
Completed Phase 2 Interventional

A Safety Study of ABI-007 for In-Stent Restenosis

NCT00093223
View directory record Official record
Conditions
Angina Pectoris, Coronary Artery Disease
Interventions
Paclitaxel Nanoparticle Albumin Bound
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 17, 2019 · Synced Jul 22, 2026, 5:15 AM EDT
Not listed Phase 2Phase 3 Interventional

PROVIDENCE:Prevention of Restenosis With Oral Rosiglitazone and the Vision Stent in Diabetics With Coronary Lesions

NCT00116792
View directory record Official record
Conditions
Coronary Artery Disease, Diabetes Mellitus
Interventions
Percutaneous Coronary Intervention (PCI)
Procedure
Lead sponsor
Gold, Herman K., MD
Individual
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 16, 2007 · Synced Jul 22, 2026, 5:15 AM EDT
Completed Not applicable Interventional

The ENDEAVOR Pharmacokinetic (PK) Registry: The Medtronic Endeavor Drug Eluting Coronary Stent System

NCT00314275
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Coronary Artery Stenting, Endeavor
Device
Lead sponsor
Medtronic Vascular
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Santa Rosa, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Jul 22, 2026, 5:15 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Tryton Post Approval Study (PAS) for the Tryton Side Branch Stent

NCT03318796
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Coronary Artery Stenting
Device
Lead sponsor
Tryton Medical, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
335 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Jul 22, 2026, 5:15 AM EDT
Completed Not applicable Interventional

The ASPECT Study - Asian Paclitaxel-Eluting Stent Clinical Trial

NCT00196079
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Coronary stent
Device
Lead sponsor
Cook Group Incorporated
Industry
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 31, 2012 · Synced Jul 22, 2026, 5:15 AM EDT
Completed Not applicable Interventional Results available

Pulmonary Artery Repair With Covered Stents

NCT01824160
View directory record Official record
Conditions
Pulmonary Stenosis, Pulmonary Regurgitation, Tetralogy of Fallot
Interventions
Repair of RV-PA Conduit Disruption
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
7 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
38
States / cities
Loma Linda, California • Los Angeles, California • San Diego, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Jul 22, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Results available

SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)

NCT00180479
View directory record Official record
Conditions
Stents, Coronary Artery Disease, Total Coronary Occlusion, Coronary Artery Restenosis, Stent Thrombosis, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis
Interventions
XIENCE V® Everolimus Eluting Coronary Stent, TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
1,002 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
65
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 56 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2011 · Synced Jul 22, 2026, 5:15 AM EDT
Completed Not applicable Interventional Results available

EXPERT CTO: Evaluation of the XIENCE PRIME™ LL and XIENCE Nano™ Everolimus Eluting Coronary Stent Coronary Stents, Performance, and Technique in Chronic Total Occlusions

NCT01435031
View directory record Official record
Conditions
Coronary Artery Disease (CAD), Chronic Total Occlusion (CTO)
Interventions
CTO Treatment Device
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Jul 22, 2026, 5:15 AM EDT
Completed Phase 4 Interventional Results available

EVOLVE Short DAPT Study

NCT02605447
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
3 months of dual antiplatelet therapy (DAPT), SYNERGY Stent System
Drug · Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
2,009 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
89
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Bakersfield, California + 75 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Jul 22, 2026, 5:15 AM EDT
Suspended Not applicable Interventional

IonMAN II Trial- Early Feasibility Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System

NCT06071702
View directory record Official record
Conditions
Coronary Stenosis, Coronary Artery Disease
Interventions
IoNIR Ridaforolimus-Eluting Coronary Stent System
Device
Lead sponsor
Medinol Ltd.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Roslyn, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Jul 22, 2026, 5:15 AM EDT